Health TrialsbyHealthPanel

6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics

ConditionType 2 Diabetes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-64
SponsorUniversity of British Columbia

About this trial

To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Exercise

    Other intervention

    In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Treadmill walking with blood flow restrictionExperimental treatment 1 intervention
Group B: Treadmill WalkingActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in T-cell oxygen consumption rate (OCR) measured before and after the 6-week intervention

T-cell OCR will be measured using a Seahorse Analyzer at baseline and after the 6-week intervention.

Time frame
0-6 weeks

Secondary outcomes

1

Change in CD4 expression before and after the 6-week intervention

The CD4 expression will be measured using flow cytometry at baseline and after the 6-week intervention.

Time frame
0-6 weeks
2

Change in CD8 expression before and after the 6-week intervention

0-6 weeks

Time frame
The CD8 expression will be measured using flow cytometry at baseline and after the 6-week intervention.
3

Change in % of T regulatory cells before and after the 6-week intervention

The % T regulatory cells will be measured using flow cytometry at baseline and after the 6-week intervention.

Time frame
0-6 weeks
4

Change in % of Th1 cells before and after the 6-week intervention

The % Th1 cells will be measured using flow cytometry at baseline and after the 6-week intervention.

Time frame
0-6 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of British Columbia

Lead sponsor

Source ClinicalTrials.gov
Apply now